ATAI - Conference and earnings call announcements

NEW YORK, May 27, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ:ATAI) ("AtaiBeckley" or "Company"), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient mental health treatments, today announced that members of the Company's management team will participate in multiple upcoming investor conferences in June 2026. Jefferies Global Healthcare Conference Dates: June 2 – 4, 2026Location: New York, NYParticipation: Fireside chat and one-on-one meetingsPresentation date and time: Wednesday, June 3, 12:15 PM ETWebcast link: https://event.summitcast.com/view/NgCqua4VVQjq9ibVWHVWca/guest_book?session_id=fpBDEvLFcur

EMP-01 demonstrated a large, clinically meaningful reduction in patient-reported SAD symptoms at Day 43: placebo-adjusted LSMD -11.5 points (p=0.002) on SPIN; placebo-adjusted LSMD -15.6 points (p=0.004) on SAFE - a 38% and 32% reduction, respectivelyPatient-perceived global improvement: 49% PGI-C responders at Day 43 compared to 12% on placeboNo severe or serious adverse events NEW YORK, April 22, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ:ATAI) ("AtaiBeckley" or "Company"), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient mental health treatments, today announced expanded Phase 2a results for EMP-

NEW YORK, April 14, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ:ATAI) ("AtaiBeckley" or "Company"), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient mental health treatments, today announced that Dr. Srinivas Rao, Co-Founder and Chief Executive Officer, will participate in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference (April 13 – 16) and a panel discussion at the Needham Virtual Psychedelics Forum (April 27). Topics for the panel will focus on late-stage clinical development strategy, FDA and DEA regulatory considerations, payer economics, and the long-term commercial adopti

Aligned with FDA on dual-trial design Phase 3 program that aims to demonstrate robust efficacy and long-term safety and that allows for flexible dosingPhase 3 program initiation remains on track for Q2 2026BPL-003 was previously granted Breakthrough Therapy designation by the FDA for treatment-resistant depressionVirtual Investor Day scheduled on March 6, 2026, to provide further detail on the BPL-003 Phase 3 clinical strategy NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ:ATAI) ("AtaiBeckley" or "Company"), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient mental health treatments,

NEW YORK, Feb. 20, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ:ATAI) ("AtaiBeckley" or "Company"), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient mental health treatments, today announced that it will host a Virtual Investor Day on Friday, March 6, 2026, from 9:00 a.m. to 12:00 p.m. ET. The event will feature presentations and live Q&A sessions with members of the Company's executive leadership team and several external key opinion leaders. Investors, analysts, and members of the media are invited to register for the live webcast. A replay will be made available following the event on the investor

NEW YORK, Feb. 17, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ:ATAI) ("AtaiBeckley" or "Company"), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient mental health treatments, today announced that Srinivas Rao, M.D., Ph.D., Co-Founder and Chief Executive Officer, and Jason Awe, Ph.D., Vice President of Investor Relations, will participate in fireside chats and host one-on-one meetings at the following investor conferences in March. TD Cowen 46th Annual Health Care Conference Format: Fireside chat, Wednesday, March 4, from 11:50am – 12:20pm EST and one-on-one meetingsLocation: Boston, Massachusetts Je

NEW YORK and AMSTERDAM, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Atai Beckley N.V. (NASDAQ:ATAI) ("AtaiBeckley" or "Company"), a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting and convenient mental health treatments, today announced that Srinivas Rao, M.D., Ph.D., Co-Founder and Chief Executive Officer, and Kevin Craig, M.D., Chief Medical Officer, are scheduled to participate in the Jefferies Global Healthcare Conference in London, UK. Details of the company's participation: Format: Fireside chat and 1x1 investor meetingsDate and Time: Fireside chat on Thursday, November 20 at 11:30 A.M. GMT/ 6:30 A.M. ETWebcast link: He

NEW YORK and AMSTERDAM, Aug. 28, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ:ATAI) ("atai" or "Company"), a clinical-stage biopharmaceutical company on a mission to develop highly effective mental health treatments to transform patient outcomes, today announced that its management is scheduled to participate in upcoming September investor conferences. Details of the Company's participation are as follows: Cantor Global Healthcare Conference 2025 Format: Fireside ChatDate: Friday, September 5th at 8:35 a.m. ETLocation: New York, NY H.C. Wainwright 27th Annual Global Investment Conference Format: Fireside ChatDate and Time: Monday, September 8th at 11:30 a.m. ETLocatio

NEW YORK and BERLIN, May 29, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences  (NASDAQ:ATAI) ("atai" or "Company"), a clinical-stage biopharmaceutical company on a mission to develop highly effective mental health treatments to transform patient outcomes, today announced that the Company's management team is scheduled to participate in the following investor conferences in June: Jefferies Global Healthcare Conference Format: Fireside ChatDate and Time: Thursday, June 5 at 9:55 A.M. EDTLocation: New YorkWebcast link: here H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference Format: Pre-recorded Fireside ChatDate and Time: Tuesday, June 17 at 7:00 A.M. EDTLocation: VirtualWebcast l

NEW YORK and BERLIN, Feb. 24, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ:ATAI) ("atai" or "Company"), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that the Company's management team is scheduled to participate in the TD Cowen 45th Annual Health Care Conference in Boston, MA from March 3-5, 2025. Details of the company's participation: Format: Fireside chat and 1x1 investor meetingsDate and Time: Fireside chat on Monday, March 3 at 11:50 A.M. ETWebcast link: Here An archived replay will be available on the Investors section of the atai website under Events for up to 90 days. About atai Life Sciencesatai

NEW YORK and BERLIN, Oct. 15, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ:ATAI) ("atai" or "Company"), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that Srinivas Rao, M.D., Ph.D., the Company's Co-founder and Co-CEO, is scheduled to participate in the 2024 Maxim Healthcare Virtual Summit taking place from October 15 – 17, 2024. Details of the company's participation: Format: Virtual fireside chat Date: Wednesday, October 16, 2024 Presentation Time: 3:30 P.M. EDTWebcast: Register here An archived replay will be available on the Investors section of the atai website under Events for up to 30 days. About at

NEW YORK and BERLIN, Sept. 04, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ:ATAI) ("atai" or "Company"), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that the Company's management team is scheduled to participate in the H.C. Wainwright 26th Annual Global Investment Conference in New York, NY from September 9-11, 2024. Details of the company's participation: Format: Fireside chat and 1x1 investor meetingsDate and Time: Fireside chat on Tuesday, September 10 at 4:30 P.M. EDTWebcast link: Here An archived replay will be available on the Investors section of the atai website under Events for up to 90 days. Ab

NEW YORK and BERLIN, Aug. 07, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ:ATAI) ("atai" or "Company"), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that the Company's management team is scheduled to participate in the Canaccord Genuity 44th Annual Growth Conference taking place in Boston, MA from August 13-15, 2024. Details of the company's participation: Format: Fireside chat and 1x1 investor meetingsDate and Time: Fireside chat on Wednesday August 14 at 11:00 A.M. EDTWebcast link: Here An archived replay will be available on the Investors section of the atai website under Events for up to 90 days. Abou

NEW YORK and BERLIN, June 26, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ:ATAI) ("atai" or "Company"), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that the Company's management team will participate in the H.C. Wainwright 5th Annual Neuro Perspectives Conference taking place on June 27, 2024. Details of the company's participation: Format: Virtual fireside chat and 1x1 investor meetingsDate and Time: Fireside chat available on-demand from Thursday, June 27 at 07:00 A.M. ETWebcast link: here An archived replay will be available on the Investors section of the atai website under Events for up to 90 days.

NEW YORK and BERLIN, May 31, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ:ATAI) ("atai" or "Company"), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that the Company's management team will participate in the Jefferies Global Healthcare Conference being held from June 4-6, 2024. Details of the company's participation: Format: Fireside ChatDate and Time: Thursday June 6 at 10:00 A.M. ETLocation: New YorkWebcast link: here The live webcast of the fireside chat will also be available on the Investors section of the atai website under Events. A replay will be available following the live event. About atai Life

NEW YORK and BERLIN, Feb. 28, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ:ATAI) ("atai"), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that management will participate in a panel discussion at the TD Cowen conference in Boston, MA, at 12:50pm ET on March 4, 2024. A live audio webcast of the panel discussion will be available on the Investors section of the atai website under Events. A replay of the webcast will be available following the live event. About atai Life Sciencesatai is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders and was founded as a r

NEW YORK and BERLIN, Oct. 06, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ:ATAI) ("atai"), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in the Jefferies Inaugural Biotech CNS/Neuro Summit being held from October 11-12, 2023. Details of the company's participation is as follows: Jefferies Inaugural Biotech CNS/Neuro Summit Format: Fireside Chat Date and Time: Wednesday, October 11th at 8:30 A.M. ET Location: New York, NY A webcast of the company's fireside chat will be available on atai's website under Events on the Investors section of the atai website: https://ir.atai.life/news-events/events/. A rep

NEW YORK and BERLIN, Sept. 14, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ:ATAI) ("atai"), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in the 2023 Cantor Fitzgerald Global Healthcare Conference. Details of the company's participation is as follows: 2023 Cantor Fitzgerald Global Healthcare Conference Format: Fireside Chat Date and Time: Thursday, September 28th at 1:50 P.M. ET Location: New York, NY A webcast of the company's fireside chat will be available on atai's website under Events on the Investors section of the atai website: https://ir.atai.life/news-events/events/. A replay will be available

NEW YORK and BERLIN, Sept. 06, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ:ATAI) ("atai"), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in upcoming September Investor Conferences. Details of the company's participation are as follows: Citi's 18th Annual BioPharma Conference Format: 1x1 Only Date: Thursday, September 7th Location: Boston, MA H.C. Wainwright 25th Annual Global Investment Conference Format: Fireside Chat Date and Time: Monday, September 11th at 4:00 P.M. ET Location: New York, NY TD Cowen 3rd Annual Novel Mechanisms in Neuropsychiatry Summit Format: Panel Date and Time: Wednesday

NEW YORK and BERLIN, June 01, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ:ATAI) ("atai"), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in upcoming June Investor Conferences. Details of the company's participation are as follows: Jefferies 2023 Healthcare ConferenceFormat: Corporate PresentationDate and Time: Friday, June 9th, 9:00 a.m. ETLocation: New York, NYH.C. Wainwright 4th Annual Neuropsychiatry Virtual ConferenceFormat: Corporate Presentation ("on-demand")Date and Time: Monday, June 26thLocation: Virtual  A webcast will be available on atai's website under Events on the Investors section of

NEW YORK and BERLIN, May 02, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ:ATAI) ("atai"), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in the 2023 Aegis Virtual Conference. Details of the company's presentation is as follows: Aegis Virtual ConferenceFormat: Corporate PresentationDate and Time: Wednesday, May 3rd, 11:30 a.m. ETLocation: Virtual A live webcast of the presentation will be available on atai's website under Events on the Investors section of the atai website: https://ir.atai.life/news-events/events/. An archived replay of the webcast will be available for up to 30 days following the presentat

NEW YORK and BERLIN, March 01, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ:ATAI) ("atai"), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in the Cowen 43rd Annual Health Care Conference. Details of the company's panel participation are as follows: Cowen 43rd Annual Health Care Conference   Format: Neuropsych Corporate Panel Date and Time: Monday, March 6th, 12:50 p.m. – 1:20 p.m. ET Location: Boston, MA A live webcast of the panel will be available on atai's website under Events on the Investors section of the atai website: https://ir.atai.life/news-events/events/. An archived replay of the webcast wil

The Women in Psychedelics Network ("WIPN" or "Network"), a network of professionals from all corners of the psychedelic industry strengthening women's voices and providing opportunities to move mental health solutions forward, today announced atai Life Sciences N.V. (NASDAQ:ATAI) ("atai"), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, as a platinum sponsor of the Network, through its philanthropic arm atai Impact. WIPN and atai are mutually aligned in their efforts to support the leadership of women in changing the way we treat mental health and in positively impacting the development of the psychedelic field. In a recent McKinsey

NEW YORK and BERLIN, Nov. 01, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (NASDAQ:ATAI) ("atai"), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in the following investor events & healthcare conferences: Financial Times Pharma and Biotech Summit in LondonFormat: Industry PanelDate and Time: Wednesday, November 9th, 9:55 a.m. – 10:40 a.m. ETConference link: Financial Times' Pharma and Biotech Summit Credit Suisse Annual Healthcare Conference in Southern CaliforniaFormat: Fireside ChatDate and Time: Wednesday, November 9th, 4:35 p.m. – 6:35 p.m. ETConference link: Credit Suisse Annual Healthcare Conference HLT

Completed enrollment of Phase 2a proof-of-concept, randomized, double-blind, placebo-controlled clinical trial of PCN-101 (R-ketamine).Last patient expected to be dosed this week, with the total number of patients expected to be around 100. Topline results expected around year-end 2022.PCN-101 is being investigated as a potentially rapid-acting therapeutic for treatment-resistant depression (TRD) with at-home administration.atai to contextualize the upcoming Phase 2a topline results at its R&D Day today at 12 pm E.T. NEW YORK and BERLIN, Oct. 25, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ:ATAI) ("atai"), a clinical-stage biopharmaceutical company focused on developing innovative

NEW YORK and BERLIN, Oct. 04, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (NASDAQ:ATAI) ("atai"), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in in the following investor events & host a virtual R&D Day in October: Roth Inaugural Healthcare Opportunities Conference in New York CityFormat: Company presentationDate and Time: Thursday, October 6th, 11:45 a.m. ET – 12:15 p.m. ETConference link: Roth Inaugural Healthcare Opportunities Conference Cantor Fitzgerald's Neurology & Psychiatry Conference in San FranciscoFormat: Industry panelsDate and Time: Thursday, October 6th, 2:10 p.m. ET – 3:10 p.m. ET & Fri

NEW YORK and BERLIN, Sept. 07, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (NASDAQ:ATAI) ("atai"), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in the following investor conferences in September: Citi's 17th Annual BioPharma Conference in BostonFormat: Industry PanelDate and Time: Wednesday, September 7th, 10:30 a.m. ET – 11:15 a.m. ETConference Link: URL H.C. Wainwright's 24th Annual Global Investment Conference in New York CityFormat: Company PresentationDate and Time: Tuesday, September 13th, 11:00 a.m. ET – 11:45 a.m. ETConference Link: URL Cowen's 2nd Annual Novel Mechanisms in Neuropsychiatry Virtual

NEW YORK and BERLIN, June 16, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (NASDAQ:ATAI) ("atai"), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in the following upcoming healthcare conferences in June: BIO International Conference                         Format: Company Presentation – In Person                        Date and Time: Thursday, June 16th, 2:45 p.m. ET – 3:15 p.m. ET                        Conference Link: URL H.C. Wainwright 1st Annual Mental Health Conference                         Format: Company Presentation – Hybrid                        Date and Time: Monday, Ju

NEW YORK, April 19, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (NASDAQ:ATAI) ("atai"), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in the following upcoming investor conference in April: Benzinga Psychedelics ConferenceFormat: Company Presentation – In Person & VirtualDate and Time: Tuesday, April 19th, 1:10 p.m. ET – 1:40 p.m. ETConference Link: URL The presentation and archived webcast will also be accessible in the Events section of atai's website. About atai Life Sciences atai is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. atai was founded

NEW YORK, March 21, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (NASDAQ:ATAI) ("atai"), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in the following upcoming investor conferences in March: Citi Winter Biotech Virtual Bus TourFormat: Fireside Chat - VirtualDate and Time: Tuesday, March 22nd, 11:00 a.m. ET – 11:40 a.m. ETConference Link: URL Maxim Group 2022 Virtual Growth ConferenceFormat: Company Presentation - VirtualDate and Time: Monday, March 28th, 2022 – Wednesday, March 30th, 2022Conference Link: URL The presentations and archived webcasts will also be accessible in the Events section of atai's webs

- Leading non-profit and commercial organizations in psychedelic science united in visions to heal mental health conditions - Donation is from atai Impact, the philanthropic arm of mental health company, atai Life Sciences - Funds will help support the general operations of MAPS, including its Health Equity Program to increase diversity, equity and inclusion in psychedelic healthcare NEW YORK and BERLIN, Feb. 16, 2022 (GLOBE NEWSWIRE) -- atai Impact, the philanthropic program of atai Life Sciences (NASDAQ:ATAI) ("atai") and the Multidisciplinary Association for Psychedelic Studies (MAPS) today announced a $500,000 donation from atai Impact to MAPS. This donation is an important demonstr

NEW YORK, Feb. 15, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (NASDAQ:ATAI) ("atai"), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in the following upcoming investor conference in February. Presentation details can be found below: Aegis ConferenceFormat: VirtualDate and Time: Thursday, February 24, 2022, 11:30 a.m. ETWebcast Link: https://bit.ly/3JuuKmV  The presentations and archived webcasts will also be accessible in the Events section of atai's website. About atai Life Sciences atai is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. atai was fo

NEW YORK, Jan. 10, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (NASDAQ:ATAI) ("atai"), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in the following upcoming investor conference today: H.C. Wainwright BioConnect Conference (Virtual)Format: Fireside ChatDate and Time: Monday, January 10th, 2022, 2:00 p.m. ETWebcast Link: URL The presentations and archived webcasts will also be accessible in the Events section of atai's website. About atai Life Sciences atai is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. atai was founded in 2018 as a response to th

NEW YORK, Nov. 05, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (NASDAQ:ATAI) ("atai"), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that it will participate in the following upcoming investor conferences in November: Presentation details can be found below: Berenberg US CEO Conference 2021Format: 1x1 MeetingsDates: Tuesday, November 9th, 2021 – Wednesday, November 10th, 2021 Credit Suisse 30th Annual Healthcare ConferenceFormat: Fireside ChatDate and Time: Thursday, November 11th, 2021, 9:40 a.m. ETWebcast Link: https://kvgo.com/cs-2021-healthcare-conf/atai-life-sciences-nov 12th Annual Jefferies London He

BERLIN, Sept. 03, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (NASDAQ:ATAI) ("atai"), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that it will participate in in the following upcoming investor conferences in September: Presentation details can be found below: Citi 16th Annual BioPharma ConferenceFormat: Panel DiscussionDate and Time: Wednesday, September 8th, 2021, 2:20 p.m. ETWebcast Link: https://kvgo.com/citi-16th-annual-biopharma-vc/panel-atai-life-sciences-sept-2021 H.C. Wainwright 23rd Annual Global Investment ConferenceFormat: PresentationDate and Time: Monday, September 13th, 2021, 9:00

BERLIN, Aug. 12, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ:ATAI) ("atai"), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, announced the launch of Revixia Life Sciences (Revixia), a wholly owned subsidiary developing Salvinorin A (SalA) to treat a variety of mental health disorders. Derived from Salvia divinorum, SalA is a unique non-nitrogenous agonist of the kappa-opioid receptor (KOR) with potential use in treatment-resistant depression (TRD), substance use disorder (SUD) and pain. Traditionally, Salvia divinorum has been used by the Mazatec people in Oaxaca, Mexico for a variety of illnesses, such as diarrhoea, headach

BERLIN, Aug. 06, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (NASDAQ:ATAI) ("atai"), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that it will participate in a fireside chat and one-on-one investor meetings at the Canaccord Genuity Growth Conference, to be held virtually from August 10-12, 2021. Presentation details can be found below: 41st Annual Canaccord Genuity Growth ConferenceFormat: Fireside chat Date and Time: Tuesday, August 10th, 2:30 p.m. ETWebcast link: https://wsw.com/webcast/canaccord60/atai/2419868 About atai Life Sciences atai is a clinical-stage biopharmaceutical company aiming to transform